Back to CVE records
Low 3.5HealthcarePublished Dec 27, 2022

CVE-2021-4291OpenMRS Admin UI Module location.gsp cross site scripting

Updated under an hour ago ()

Does this affect you?

It affects OpenMRS Admin UI Module. Add what you run to find out whether that includes you.

EPSS puts the chance of exploitation in the next 30 days at 0.95%, higher than 60% of scored CVEs.

A vulnerability was found in OpenMRS Admin UI Module up to 1.5.x. It has been declared as problematic. This vulnerability affects unknown code of the file omod/src/main/webapp/pages/metadata/locations/location.gsp. The manipulation leads to cross site scripting. The attack can be initiated remotely. Upgrading to version 1.6.0 is able to address this issue. The name of the patch is a7eefb5f69f6c50a3bffcb138bb8ea57cb41a9b6. It is recommended to upgrade the affected component. The identifier of this vulnerability is VDB-216916.

CVSS
3.5 LOW (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:N/I:L/A:N
Weakness (CWE)
CWE-79
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
0.95% (percentile 60)
Assigned by
VulDB
NVD analysis
Modified
Record last updated
Aug 3, 2024
First seen by InfoSec Signals
Oct 12, 2026

Affected products

Affected products
OpenMRS Admin UI Module
openmrs:admin_ui_module (from the name)
1.0; 1.1; 1.2; 1.3; 1.4; 1.5
CNA record
openmrs admin_ui_module
openmrs:admin_ui_module
before 1.6.0
NVD

References

  • vdb-entry, permissions-required, third-party-advisory
  • signature, permissions-required, third-party-advisory
  • issue-tracking, patch, third-party-advisory
  • patch, third-party-advisory
  • patch, release-notes, third-party-advisory

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.